Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Takeda’s Japan Ethical Sales Sag 6.8% on LLP Transfer, but Underlining Revenue Grows
May 11, 2017
- Fujifilm Invests 170 Million Yen in Regenerative Medicine Startup
May 11, 2017
- Takeda, UK Bioventure GammaDelta Pair Up for Development of New Immunotherapies Based on T cells
May 11, 2017
- Sales Rep Survey - 2: Drug Makers Exploring New Values amid Shift to Community-Based Care
May 10, 2017
- Meiji Seika Pharma Forms Generic Subsidiary
May 10, 2017
- Takeda Calls off Hib Vaccine Launch on GSK’s Production Exit
May 10, 2017
- Japanese Drug Production Could Shrink to 6.8 Trillion Yen in 2024: Yano Research Institute
May 10, 2017
- BIKEN, Mitsubishi Tanabe Reach Final Agreement on Vaccine Joint Venture Slated to Begin Operation in September
May 10, 2017
- Daiichi Sankyo Starts Edoxaban Clinical Study in AF Patients following TAVI
May 10, 2017
- Eisai Suffers Setback in US Patent Litigation over Aloxi
May 9, 2017
- Mitsubishi Tanabe’s ALS Med Gets FDA Greenlight
May 9, 2017
- Sales Rep Survey - 1: Foreign Drug Makers’ Downsizing Drive Unabated
May 9, 2017
- 60% of Drug Makers Increase New Grad Hires in FY2017, Otsuka Tops List: Jiho Tally
May 9, 2017
- Brexpiprazole Delivers Mixed Results on AD Agitation: Otsuka, Lundbeck
May 8, 2017
- Debiopharm’s Appeal on Elplat Patent Suit Dismissed: Nichi-Iko
May 8, 2017
- Takeda Gets FDA Nod for Ariad’s ALK Hopeful Brigatinib
May 8, 2017
- Keytruda Filed in Japan for Urothelial Cancer: MSD
April 28, 2017
- Harvoni Filed for Genotype 2 Hepatitis C: Gilead Japan
April 28, 2017
- Takeda Joins Hands with Harrington Institute on Rare Disease Therapeutics
April 28, 2017
- Pfizer Files Japan NDA for ALL Treatment
April 28, 2017
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…